25 XP   0   0   10

X4 Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse X4 Pharmaceuticals Inc together

PenkeI guess you are interested in X4 Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of X4 Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about X4 Pharmaceuticals Inc

I send you an email if I find something interesting about X4 Pharmaceuticals Inc.

Quick analysis of X4 Pharmaceuticals Inc (30 sec.)










What can you expect buying and holding a share of X4 Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.44
When do you have the money?
1 year
How often do you get paid?
13.8%

What is your share worth?

Current worth
$0.26
Expected worth in 1 year
$0.21
How sure are you?
34.5%

+ What do you gain per year?

Total Gains per Share
$0.39
Return On Investment
30.8%

For what price can you sell your share?

Current Price per Share
$1.26
Expected price per share
$1.07 - $1.68
How sure are you?
50%

1. Valuation of X4 Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)

$1.26

Intrinsic Value Per Share

$-5.15 - $-6.00

Total Value Per Share

$-4.90 - $-5.74

2. Growth of X4 Pharmaceuticals Inc (5 min.)




Is X4 Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$51m$51.3m$12m19.0%

How much money is X4 Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$33.2m-$24m-$9.1m-27.5%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of X4 Pharmaceuticals Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#477 / 1016

Most Revenue
#816 / 1016

Most Profit
#817 / 1016

Most Efficient
#262 / 1016

What can you expect buying and holding a share of X4 Pharmaceuticals Inc? (5 min.)

Welcome investor! X4 Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of X4 Pharmaceuticals Inc.

What can you expect buying and holding a share of X4 Pharmaceuticals Inc?

First you should know what it really means to hold a share of X4 Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of X4 Pharmaceuticals Inc is $1.26. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of X4 Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in X4 Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.26. Based on the TTM, the Book Value Change Per Share is $-0.01 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.02 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.11 per quarter.
Based on historical numbers we can estimate the returns while holding a share of X4 Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.10-7.6%-0.15-11.5%-0.14-11.4%-0.12-9.6%-0.10-7.8%
Usd Book Value Change Per Share-0.09-6.8%-0.01-1.0%-0.02-1.5%0.010.5%0.010.7%
Usd Dividend Per Share0.000.0%0.118.7%0.000.0%0.032.3%0.021.6%
Usd Total Gains Per Share-0.09-6.8%0.107.7%-0.02-1.5%0.042.8%0.032.3%
Usd Price Per Share0.84-1.18-1.35-6.06-5.67-
Price to Earnings Ratio-2.18--7.11--2.41--17.83--20.51-
Price-to-Total Gains Ratio-9.75--261.18--7.29--54.31--62.44-
Price to Book Ratio3.26-3.36-4.60-43.47-35.49-
Price-to-Total Gains Ratio-9.75--261.18--7.29--54.31--62.44-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.26
Number of shares793
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.110.03
Usd Book Value Change Per Share-0.010.01
Usd Total Gains Per Share0.100.04
Gains per Quarter (793 shares)76.8328.26
Gains per Year (793 shares)307.33113.03
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1347-402979320103
2695-8060418541216
31042-12091127861329
41390-161121837181442
51737-2011525463102555
62085-2411832556122668
72432-2812139649143781
82780-3212446741163894
93127-36127538341831007
103475-40130609272041120

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.029.00.00.0%0.029.00.00.0%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%7.013.00.035.0%9.018.02.031.0%9.018.02.031.0%
Dividend per Share2.00.02.050.0%3.00.09.025.0%4.00.016.020.0%4.00.025.013.8%4.00.025.013.8%
Total Gains per Share1.03.00.025.0%5.07.00.041.7%8.012.00.040.0%10.017.02.034.5%10.017.02.034.5%

Fundamentals of X4 Pharmaceuticals Inc

About X4 Pharmaceuticals Inc

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

Fundamental data was last updated by Penke on 2024-04-12 22:42:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of X4 Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit X4 Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare X4 Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of X4 Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-34.1%+34.1%
5Y-34.1%10Y-32.7%-1.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--199.6%+199.6%
TTM--213.0%+213.0%
YOY--279.3%+279.3%
5Y-34.1%-438.4%+404.3%
10Y-32.7%-605.5%+572.8%
1.1.2. Return on Assets

Shows how efficient X4 Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare X4 Pharmaceuticals Inc to the Biotechnology industry mean.
  • -13.0% Return on Assets means that X4 Pharmaceuticals Inc generated $-0.13 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of X4 Pharmaceuticals Inc:

  • The MRQ is -13.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -19.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-13.0%TTM-19.6%+6.7%
TTM-19.6%YOY-21.6%+1.9%
TTM-19.6%5Y-16.5%-3.2%
5Y-16.5%10Y-23.3%+6.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.0%-13.5%+0.5%
TTM-19.6%-12.9%-6.7%
YOY-21.6%-11.8%-9.8%
5Y-16.5%-14.1%-2.4%
10Y-23.3%-16.0%-7.3%
1.1.3. Return on Equity

Shows how efficient X4 Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare X4 Pharmaceuticals Inc to the Biotechnology industry mean.
  • -37.4% Return on Equity means X4 Pharmaceuticals Inc generated $-0.37 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of X4 Pharmaceuticals Inc:

  • The MRQ is -37.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -51.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-37.4%TTM-51.5%+14.0%
TTM-51.5%YOY-50.1%-1.3%
TTM-51.5%5Y-84.9%+33.4%
5Y-84.9%10Y-67.3%-17.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-37.4%-16.9%-20.5%
TTM-51.5%-16.1%-35.4%
YOY-50.1%-15.1%-35.0%
5Y-84.9%-19.9%-65.0%
10Y-67.3%-20.9%-46.4%

1.2. Operating Efficiency of X4 Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient X4 Pharmaceuticals Inc is operating .

  • Measures how much profit X4 Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare X4 Pharmaceuticals Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of X4 Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-31.9%+31.9%
5Y-31.9%10Y-31.0%-0.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--295.1%+295.1%
TTM--225.8%+225.8%
YOY--288.4%+288.4%
5Y-31.9%-477.4%+445.5%
10Y-31.0%-625.6%+594.6%
1.2.2. Operating Ratio

Measures how efficient X4 Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of X4 Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y0.375-0.375
5Y0.37510Y0.385-0.009
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.090-3.090
TTM-3.264-3.264
YOY-3.783-3.783
5Y0.3755.679-5.304
10Y0.3857.894-7.509

1.3. Liquidity of X4 Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if X4 Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 5.34 means the company has $5.34 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of X4 Pharmaceuticals Inc:

  • The MRQ is 5.340. The company is very able to pay all its short-term debts. +2
  • The TTM is 6.106. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.340TTM6.106-0.767
TTM6.106YOY4.483+1.624
TTM6.1065Y7.121-1.015
5Y7.12110Y6.221+0.900
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.3403.914+1.426
TTM6.1064.220+1.886
YOY4.4835.388-0.905
5Y7.1216.045+1.076
10Y6.2216.406-0.185
1.3.2. Quick Ratio

Measures if X4 Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare X4 Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Quick Ratio of 5.69 means the company can pay off $5.69 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of X4 Pharmaceuticals Inc:

  • The MRQ is 5.688. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 6.221. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ5.688TTM6.221-0.534
TTM6.221YOY4.255+1.967
TTM6.2215Y6.913-0.691
5Y6.91310Y6.009+0.904
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.6883.572+2.116
TTM6.2213.998+2.223
YOY4.2555.390-1.135
5Y6.9135.969+0.944
10Y6.0096.287-0.278

1.4. Solvency of X4 Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of X4 Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare X4 Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.65 means that X4 Pharmaceuticals Inc assets are financed with 65.3% credit (debt) and the remaining percentage (100% - 65.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of X4 Pharmaceuticals Inc:

  • The MRQ is 0.653. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.621. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.653TTM0.621+0.032
TTM0.621YOY0.560+0.061
TTM0.6215Y0.472+0.149
5Y0.47210Y1.281-0.809
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6530.336+0.317
TTM0.6210.334+0.287
YOY0.5600.269+0.291
5Y0.4720.366+0.106
10Y1.2810.390+0.891
1.4.2. Debt to Equity Ratio

Measures if X4 Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare X4 Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 188.2% means that company has $1.88 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of X4 Pharmaceuticals Inc:

  • The MRQ is 1.882. The company is just able to pay all its debts with equity.
  • The TTM is 1.645. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ1.882TTM1.645+0.237
TTM1.645YOY1.302+0.344
TTM1.6455Y4.619-2.974
5Y4.61910Y3.353+1.267
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8820.382+1.500
TTM1.6450.396+1.249
YOY1.3020.335+0.967
5Y4.6190.434+4.185
10Y3.3530.465+2.888

2. Market Valuation of X4 Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings X4 Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare X4 Pharmaceuticals Inc to the Biotechnology industry mean.
  • A PE ratio of -2.18 means the investor is paying $-2.18 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of X4 Pharmaceuticals Inc:

  • The EOD is -3.273. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.179. Based on the earnings, the company is expensive. -2
  • The TTM is -7.114. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.273MRQ-2.179-1.094
MRQ-2.179TTM-7.114+4.935
TTM-7.114YOY-2.414-4.700
TTM-7.1145Y-17.826+10.712
5Y-17.82610Y-20.510+2.684
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.273-2.259-1.014
MRQ-2.179-2.569+0.390
TTM-7.114-2.664-4.450
YOY-2.414-4.120+1.706
5Y-17.826-6.258-11.568
10Y-20.510-6.171-14.339
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of X4 Pharmaceuticals Inc:

  • The EOD is -2.254. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.501. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.400. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.254MRQ-1.501-0.753
MRQ-1.501TTM-2.400+0.899
TTM-2.400YOY-2.786+0.386
TTM-2.4005Y-18.258+15.858
5Y-18.25810Y-17.895-0.363
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.254-2.924+0.670
MRQ-1.501-3.246+1.745
TTM-2.400-3.488+1.088
YOY-2.786-5.620+2.834
5Y-18.258-8.315-9.943
10Y-17.895-8.826-9.069
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of X4 Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.26 means the investor is paying $3.26 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of X4 Pharmaceuticals Inc:

  • The EOD is 4.901. Based on the equity, the company is fair priced.
  • The MRQ is 3.264. Based on the equity, the company is fair priced.
  • The TTM is 3.363. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD4.901MRQ3.264+1.638
MRQ3.264TTM3.363-0.099
TTM3.363YOY4.601-1.239
TTM3.3635Y43.471-40.109
5Y43.47110Y35.491+7.980
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.9011.851+3.050
MRQ3.2642.090+1.174
TTM3.3632.095+1.268
YOY4.6012.844+1.757
5Y43.4713.466+40.005
10Y35.4913.815+31.676
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of X4 Pharmaceuticals Inc.

3.1. Institutions holding X4 Pharmaceuticals Inc

Institutions are holding 61.373% of the shares of X4 Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Bain Capital Life Sciences Investors, LLC10.07261.3596169157849551965.9847
2023-12-31NEA Management Company, LLC8.9240.83751498679300
2023-12-31BlackRock Inc5.01230.000284175242606833.1959
2023-12-31Vanguard Group Inc4.76890.000280088651841482.3534
2023-12-31Orbimed Advisors, LLC4.24770.1195713351500
2023-12-31Kingdon Capital Management LLC4.13690.36569473664973683252.0001
2023-12-31Adage Capital Partners Gp LLC2.54640.0074427631500
2023-12-31Sio Capital Management, LLC2.13680.6851358842798942438.0694
2023-12-31Perceptive Advisors LLC2.11120.0664354545400
2023-12-31AXA SA1.83020.00833073532-74333-2.3614
2023-12-31Geode Capital Management, LLC1.66870.000328024491595346.0363
2023-12-31State Street Corporation1.44560.00012427789491632.0669
2023-12-31Armistice Capital, LLC1.15280.02221936000-420000-17.8268
2023-09-30Citadel Advisors Llc1.0710.00041798628-1275071-41.4833
2023-12-31UBS O'Connor LLC1.03790.1052174303818305211.7342
2023-12-31Millennium Management LLC0.9910.00061664317-1951647-53.9731
2023-12-31Northern Trust Corp0.6330.00021062985-4708-0.441
2023-12-31GSA Capital Partners LLP0.56280.066794517132358452.0577
2023-12-31Parkman Healthcare Partners LLC0.45690.0906767332-32668-4.0835
2023-09-30Point72 Asset Management, L.P.0.3870.002165000000
Total 55.19373.737692691284+4320040+4.7%

3.2. Funds holding X4 Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv3.00240.00035027099-256850-4.8609
2024-02-29iShares Russell 2000 ETF1.7620.00462950184-482-0.0163
2024-01-31UTM IM GBP AXA Framlington Biotech1.76180.4362294982100
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.07950.0017180745700
2023-11-30MEDICAL BioHealth EUR Acc1.06310.2079178003400
2023-12-31Fidelity Small Cap Index0.73060.0041223244134511.1118
2024-01-31Fidelity Extended Market Index0.47170.001778974900
2024-01-31APO Medical Opportunities R0.42860.070371762300
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.42440.001771060000
2024-02-01iShares Russell 2000 Value ETF0.32510.00395443836880.1265
2024-02-29iShares Russell 2000 Growth ETF0.31850.0046533310-620-0.1161
2024-02-29State St Russell Sm Cap® Indx SL Cl I0.2710.004745380000
2024-02-29Vanguard Russell 2000 ETF0.26420.0045442300351458.6318
2024-02-29Simplify Propel Opportunities ETF0.23890.332840000000
2023-12-31Royce Micro Cap Trust0.23190.0626388363269357226.339
2023-12-31NT R2000 Index Fund - NL0.1860.0036311379-38845-11.0915
2024-02-29Schwab Small Cap Index0.16810.004628145700
2024-02-29iShares Micro-Cap ETF0.16550.029527711200
2023-09-30BlackRock Extended Mkt Composite0.15880.002126596521540.8165
2023-12-31RIM Global Bioscience EUR0.15450.211425863900
Total 13.20661.392722112519+23998+0.1%

3.3. Insider Transactions

Insiders are holding 0.832% of the shares of X4 Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-11Arthur TaverasSELL142350.88
2024-03-11Mary DibiaseSELL154090.88
2024-03-11Paula RaganSELL496780.88
2024-03-11Adam S. MostafaSELL525000.88
2024-02-12Adam S MostafaSELL277211.01
2024-02-12Arthur TaverasSELL7871.01
2024-02-12Mary DibiaseSELL36831.01
2024-02-12Paula RaganSELL216951.01
2023-11-03Paula RaganSELL399060.9
2023-11-01Paula RaganSELL1995310.73
2023-11-01Mary DibiaseSELL676950.73
2023-11-01Mark BaldrySELL102570.73
2023-11-01Adam S MostafaSELL2306450.73
2023-09-08Mary DibiaseSELL26421.25
2023-08-18Michael S WyzgaBUY250001.2
2023-08-10Murray StewartSELL1300561.06
2023-06-30Adam S MostafaSELL26411.89
2023-06-30Mary DibiaseSELL4641.89
2023-06-23Adam S MostafaSELL54171.93
2023-06-23Mary DibiaseSELL8571.93

4. Summary

4.1. Key Performance Indicators

The key performance indicators of X4 Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.086-0.013-85%-0.019-78%0.006-1440%0.009-1071%
Book Value Per Share--0.2570.351-27%0.306-16%0.418-38%0.296-13%
Current Ratio--5.3406.106-13%4.483+19%7.121-25%6.221-14%
Debt To Asset Ratio--0.6530.621+5%0.560+17%0.472+38%1.281-49%
Debt To Equity Ratio--1.8821.645+14%1.302+45%4.619-59%3.353-44%
Dividend Per Share---0.110-100%-0%0.029-100%0.020-100%
Eps---0.096-0.145+51%-0.144+49%-0.121+26%-0.098+2%
Free Cash Flow Per Share---0.140-0.125-11%-0.126-10%-0.104-26%-0.086-38%
Free Cash Flow To Equity Per Share---0.1390.108-229%-0.032-77%0.029-574%0.025-649%
Gross Profit Margin--1.0001.0000%1.142-12%1.028-3%1.020-2%
Intrinsic Value_10Y_max---6.001--------
Intrinsic Value_10Y_min---5.155--------
Intrinsic Value_1Y_max---0.495--------
Intrinsic Value_1Y_min---0.486--------
Intrinsic Value_3Y_max---1.568--------
Intrinsic Value_3Y_min---1.496--------
Intrinsic Value_5Y_max---2.740--------
Intrinsic Value_5Y_min---2.536--------
Market Cap211601880.000+21%166764674.000213734843.500-22%227472021.000-27%1020549179.900-84%954112550.276-83%
Net Profit Margin----0%-0%-0.3410%-0.3270%
Operating Margin----0%-0%-0.3190%-0.3100%
Operating Ratio----0%-0%0.375-100%0.385-100%
Pb Ratio4.901+33%3.2643.363-3%4.601-29%43.471-92%35.491-91%
Pe Ratio-3.273-50%-2.179-7.114+226%-2.414+11%-17.826+718%-20.510+841%
Price Per Share1.260+33%0.8391.185-29%1.355-38%6.059-86%5.669-85%
Price To Free Cash Flow Ratio-2.254-50%-1.501-2.400+60%-2.786+86%-18.258+1117%-17.895+1092%
Price To Total Gains Ratio-14.642-50%-9.749-261.183+2579%-7.292-25%-54.306+457%-62.442+540%
Quick Ratio--5.6886.221-9%4.255+34%6.913-18%6.009-5%
Return On Assets---0.130-0.196+51%-0.216+66%-0.165+27%-0.233+79%
Return On Equity---0.374-0.515+37%-0.501+34%-0.849+127%-0.673+80%
Total Gains Per Share---0.0860.097-189%-0.019-78%0.036-341%0.029-397%
Usd Book Value--51099000.00063440750.000-19%51378500.000-1%71064900.000-28%50262172.414+2%
Usd Book Value Change Per Share---0.086-0.013-85%-0.019-78%0.006-1440%0.009-1071%
Usd Book Value Per Share--0.2570.351-27%0.306-16%0.418-38%0.296-13%
Usd Dividend Per Share---0.110-100%-0%0.029-100%0.020-100%
Usd Eps---0.096-0.145+51%-0.144+49%-0.121+26%-0.098+2%
Usd Free Cash Flow---27782000.000-22871000.000-18%-21102750.000-24%-17790700.000-36%-14753586.207-47%
Usd Free Cash Flow Per Share---0.140-0.125-11%-0.126-10%-0.104-26%-0.086-38%
Usd Free Cash Flow To Equity Per Share---0.1390.108-229%-0.032-77%0.029-574%0.025-649%
Usd Market Cap211601880.000+21%166764674.000213734843.500-22%227472021.000-27%1020549179.900-84%954112550.276-83%
Usd Price Per Share1.260+33%0.8391.185-29%1.355-38%6.059-86%5.669-85%
Usd Profit---19130000.000-33214750.000+74%-24075250.000+26%-21639700.000+13%-17759068.966-7%
Usd Revenue----0%-0%325000.000-100%344827.586-100%
Usd Total Gains Per Share---0.0860.097-189%-0.019-78%0.036-341%0.029-397%
 EOD+5 -3MRQTTM+8 -23YOY+9 -215Y+10 -2410Y+11 -23

4.2. Fundamental Score

Let's check the fundamental score of X4 Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-3.273
Price to Book Ratio (EOD)Between0-14.901
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than15.688
Current Ratio (MRQ)Greater than15.340
Debt to Asset Ratio (MRQ)Less than10.653
Debt to Equity Ratio (MRQ)Less than11.882
Return on Equity (MRQ)Greater than0.15-0.374
Return on Assets (MRQ)Greater than0.05-0.130
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of X4 Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.240
Ma 20Greater thanMa 501.343
Ma 50Greater thanMa 1001.103
Ma 100Greater thanMa 2000.947
OpenGreater thanClose1.180
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets147,258
Total Liabilities96,159
Total Stockholder Equity51,099
 As reported
Total Liabilities 96,159
Total Stockholder Equity+ 51,099
Total Assets = 147,258

Assets

Total Assets147,258
Total Current Assets122,076
Long-term Assets25,182
Total Current Assets
Cash And Cash Equivalents 99,466
Short-term Investments 15,000
Net Receivables 562
Other Current Assets 7,048
Total Current Assets  (as reported)122,076
Total Current Assets  (calculated)122,076
+/-0
Long-term Assets
Property Plant Equipment 6,395
Goodwill 17,351
Long-term Assets Other 654
Long-term Assets  (as reported)25,182
Long-term Assets  (calculated)24,400
+/- 782

Liabilities & Shareholders' Equity

Total Current Liabilities22,862
Long-term Liabilities73,297
Total Stockholder Equity51,099
Total Current Liabilities
Short-term Debt 1,099
Accounts payable 8,947
Other Current Liabilities 12,816
Total Current Liabilities  (as reported)22,862
Total Current Liabilities  (calculated)22,862
+/-0
Long-term Liabilities
Long term Debt 54,570
Capital Lease Obligations 3,711
Long-term Liabilities Other 432
Long-term Liabilities  (as reported)73,297
Long-term Liabilities  (calculated)58,713
+/- 14,584
Total Stockholder Equity
Common Stock167
Retained Earnings -477,905
Accumulated Other Comprehensive Income -119
Other Stockholders Equity 528,956
Total Stockholder Equity (as reported)51,099
Total Stockholder Equity (calculated)51,099
+/-0
Other
Capital Stock167
Cash and Short Term Investments 114,466
Common Stock Shares Outstanding 198,766
Liabilities and Stockholders Equity 147,258
Net Debt -41,185
Net Invested Capital 105,669
Net Working Capital 99,214
Property Plant and Equipment Gross 8,014
Short Long Term Debt Total 58,281



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
> Total Assets 
7,604
0
0
37,162
81,254
69,221
57,210
45,901
36,004
62,549
133,507
109,537
160,698
153,717
142,534
133,126
122,871
161,035
141,659
120,517
117,176
99,625
81,019
155,586
124,405
173,399
173,399
173,293
147,258
147,258173,293173,399173,399124,405155,58681,01999,625117,176120,517141,659161,035122,871133,126142,534153,717160,698109,537133,50762,54936,00445,90157,21069,22181,25437,162007,604
   > Total Current Assets 
5,716
0
0
33,268
80,833
68,525
56,562
44,934
35,080
26,223
96,649
79,215
129,278
121,950
109,887
93,913
83,307
119,959
101,371
80,700
87,878
70,881
52,585
128,677
98,222
147,649
147,649
147,872
122,076
122,076147,872147,649147,64998,222128,67752,58570,88187,87880,700101,371119,95983,30793,913109,887121,950129,27879,21596,64926,22335,08044,93456,56268,52580,83333,268005,716
       Cash And Cash Equivalents 
3,035
0
0
26,254
76,793
63,999
49,940
40,753
30,754
22,299
90,180
76,251
126,184
115,054
103,744
88,812
78,708
114,945
95,161
76,393
81,787
66,427
47,378
121,718
93,406
136,428
136,428
131,581
99,466
99,466131,581136,428136,42893,406121,71847,37866,42781,78776,39395,161114,94578,70888,812103,744115,054126,18476,25190,18022,29930,75440,75349,94063,99976,79326,254003,035
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,881
4,881
10,102
15,000
15,00010,1024,8814,8810000000000000000000000000
       Net Receivables 
1,345
0
0
1,454
1,608
1,926
2,178
2,870
2,859
1,552
1,708
1,730
1,998
3,416
509
629
917
768
1,053
646
747
868
843
1,152
658
820
820
393
562
5623938208206581,1528438687476461,0537689176295093,4161,9981,7301,7081,5522,8592,8702,1781,9261,6081,454001,345
       Inventory 
1,246
0
0
5,306
355
2,262
51
51
0
0
3,163
0
0
0
0
0
0
0
0
0
0
0
-843
0
0
0
0
0
0
000000-843000000000003,1630051512,2623555,306001,246
       Other Current Assets 
90
0
0
254
2,077
338
4,393
1,260
1,467
2,372
1,598
1,234
1,096
3,480
5,634
4,472
3,682
4,246
5,157
3,661
5,344
3,586
5,207
5,807
4,158
5,520
5,520
5,796
7,048
7,0485,7965,5205,5204,1585,8075,2073,5865,3443,6615,1574,2463,6824,4725,6343,4801,0961,2341,5982,3721,4671,2604,3933382,0772540090
   > Long-term Assets 
1,888
0
0
3,894
421
696
648
967
924
36,325
36,858
30,322
31,420
31,767
32,647
39,213
39,564
41,076
40,288
39,817
29,298
28,744
28,434
26,909
26,183
25,750
25,750
25,421
25,182
25,18225,42125,75025,75026,18326,90928,43428,74429,29839,81740,28841,07639,56439,21332,64731,76731,42030,32236,85836,3259249676486964213,894001,888
       Property Plant Equipment 
519
0
0
479
421
384
353
323
285
2,975
2,445
2,458
2,362
2,278
2,065
9,556
9,197
11,576
11,175
10,703
10,224
9,747
9,285
8,333
7,830
7,320
7,320
6,826
6,395
6,3956,8267,3207,3207,8308,3339,2859,74710,22410,70311,17511,5769,1979,5562,0652,2782,3622,4582,4452,97528532335338442147900519
       Goodwill 
0
0
0
0
0
0
0
0
0
27,407
27,109
27,109
27,109
27,109
27,109
27,109
27,109
27,109
27,109
27,109
17,351
17,351
17,351
17,351
17,351
17,351
17,351
17,351
17,351
17,35117,35117,35117,35117,35117,35117,35117,35117,35127,10927,10927,10927,10927,10927,10927,10927,10927,10927,10927,407000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
4,900
4,900
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000004,9004,900000000000
       Long-term Assets Other 
1,369
0
0
3,415
1,303
312
295
644
639
1,043
2,404
755
1,949
2,380
3,473
2,548
3,258
2,391
2,004
2,005
1,723
1,646
1,798
1,225
1,002
1,079
1,079
1,244
654
6541,2441,0791,0791,0021,2251,7981,6461,7232,0052,0042,3913,2582,5483,4732,3801,9497552,4041,0436396442953121,3033,415001,369
> Total Liabilities 
64,166
0
0
25,562
22,547
20,798
19,446
18,004
14,404
33,108
37,339
30,430
31,478
34,926
37,650
43,418
50,072
54,098
139,784
51,838
52,764
49,911
50,946
81,535
72,729
105,864
105,864
105,699
96,159
96,159105,699105,864105,86472,72981,53550,94649,91152,76451,838139,78454,09850,07243,41837,65034,92631,47830,43037,33933,10814,40418,00419,44620,79822,54725,5620064,166
   > Total Current Liabilities 
12,060
0
0
13,254
7,681
9,297
10,214
8,853
5,398
16,450
13,204
8,279
9,447
7,950
10,781
13,179
11,948
14,672
13,120
13,232
14,023
14,970
22,002
22,324
19,483
22,251
22,251
25,432
22,862
22,86225,43222,25122,25119,48322,32422,00214,97014,02313,23213,12014,67211,94813,17910,7817,9509,4478,27913,20416,4505,3988,85310,2149,2977,68113,2540012,060
       Short-term Debt 
5,162
0
0
2,309
2,314
2,318
3,486
2,908
1,687
6,139
5,011
878
898
916
940
756
786
875
985
1,734
1,870
4,524
9,743
2,513
1,729
1,912
1,912
1,116
1,099
1,0991,1161,9121,9121,7292,5139,7434,5241,8701,7349858757867569409168988785,0116,1391,6872,9083,4862,3182,3142,309005,162
       Short Long Term Debt 
0
0
0
0
1,667
0
0
0
1,687
5,298
4,151
0
0
0
0
0
0
0
0
693
795
3,415
8,607
14,621
1,315
554
764
0
0
007645541,31514,6218,6073,415795693000000004,1515,2981,6870001,6670000
       Accounts payable 
1,645
0
0
4,164
1,893
1,108
2,137
2,126
545
6,132
3,099
1,704
2,088
1,248
1,838
3,891
3,144
3,091
2,528
2,424
4,283
3,569
3,677
7,777
5,992
5,108
5,108
8,132
8,947
8,9478,1325,1085,1085,9927,7773,6773,5694,2832,4242,5283,0913,1443,8911,8381,2482,0881,7043,0996,1325452,1262,1371,1081,8934,164001,645
       Other Current Liabilities 
4,749
0
0
5,716
844
5,141
3,879
3,092
4,116
4,179
5,094
5,697
6,461
5,786
8,003
8,532
8,018
10,706
9,607
9,074
7,870
6,877
8,582
12,034
11,762
15,231
15,231
16,184
12,816
12,81616,18415,23115,23111,76212,0348,5826,8777,8709,0749,60710,7068,0188,5328,0035,7866,4615,6975,0944,1794,1163,0923,8795,1418445,716004,749
   > Long-term Liabilities 
52,106
0
0
12,308
14,866
11,501
9,232
9,151
9,006
16,658
24,135
22,151
22,031
26,976
26,869
30,239
38,124
39,426
126,664
38,606
38,741
34,941
28,944
59,211
53,246
83,613
83,613
80,267
73,297
73,29780,26783,61383,61353,24659,21128,94434,94138,74138,606126,66439,42638,12430,23926,86926,97622,03122,15124,13516,6589,0069,1519,23211,50114,86612,3080052,106
       Long term Debt Total 
0
0
0
0
0
0
0
0
7,894
13,365
21,748
19,986
20,097
25,266
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000025,26620,09719,98621,74813,3657,89400000000
       Warrants
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,875
1,875
0
0
0
0
0
0
0
0
0
0
00000000001,8751,87500000000000000000
       Other Liabilities 
0
0
0
0
1,356
0
0
0
1,353
18
18
18
16
26
26
25
462
2,366
2,309
496
826
650
314
312
23,304
0
48,653
0
0
0048,653023,3043123146508264962,3092,366462252626161818181,3530001,3560000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
23,131
17,692
47,179
0
0
0047,17917,69223,131000000000000000000000000
> Total Stockholder Equity
-56,562
0
0
11,600
58,707
48,423
37,764
27,897
21,600
29,441
96,168
79,107
129,220
118,791
104,884
89,708
72,799
106,937
1,875
68,679
64,412
49,714
30,073
74,051
51,676
67,535
67,535
67,594
51,099
51,09967,59467,53567,53551,67674,05130,07349,71464,41268,6791,875106,93772,79989,708104,884118,791129,22079,10796,16829,44121,60027,89737,76448,42358,70711,60000-56,562
   Common Stock
1
0
0
8
15
15
14
14
15
7
13
12
16
16
16
16
16
1,899
1,875
25
28
31
31
122
122
164
164
165
167
167165164164122122313128251,8751,89916161616161213715141415158001
   Retained Earnings -477,905-458,775-456,470-456,470-400,758-376,738-326,048-304,836-282,871-252,664-232,489-212,851-194,175-175,775-158,326-143,182-132,044-121,207-103,493-90,110-135,286-125,928-115,028-102,895-92,265-81,07800-58,388
   Accumulated Other Comprehensive Income 
834
0
0
243
127
-93
177
144
241
23
-42
-119
-119
-119
-119
-119
-119
-119
-119
-119
-119
-119
-119
-119
-119
-119
-119
-119
-119
-119-119-119-119-119-119-119-119-119-119-119-119-119-119-119-119-119-119-4223241144177-9312724300834
   Capital Surplus 
0
0
0
0
0
0
0
0
156,630
119,521
199,690
200,421
261,367
262,076
0
0
267,077
318,008
319,921
321,437
0
0
356,209
409,533
450,786
452,431
523,960
0
0
00523,960452,431450,786409,533356,20900321,437319,921318,008267,07700262,076261,367200,421199,690119,521156,63000000000
   Treasury Stock00000000000000000000000000000
   Other Stockholders Equity 
991
0
0
92,427
150,830
151,396
152,601
153,667
156,630
56,972
66,183
90,884
261,367
262,076
263,313
265,586
72,902
318,008
319,921
321,437
347,374
354,638
356,209
450,786
452,431
523,960
523,960
67,594
528,956
528,95667,594523,960523,960452,431450,786356,209354,638347,374321,437319,921318,00872,902265,586263,313262,076261,36790,88466,18356,972156,630153,667152,601151,396150,83092,42700991



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-1,996
Gross Profit-1,996-1,996
 
Operating Income (+$)
Gross Profit-1,996
Operating Expense-105,526
Operating Income-107,522-107,522
 
Operating Expense (+$)
Research Development70,021
Selling General Administrative32,141
Selling And Marketing Expenses0
Operating Expense105,526102,162
 
Net Interest Income (+$)
Interest Income3,335
Interest Expense-5,777
Other Finance Cost-742
Net Interest Income-1,700
 
Pretax Income (+$)
Operating Income-107,522
Net Interest Income-1,700
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-101,089-113,955
EBIT - interestExpense = -113,299
-101,089
-95,390
Interest Expense5,777
Earnings Before Interest and Taxes (EBIT)-107,522-95,312
Earnings Before Interest and Taxes (EBITDA)-105,526
 
After tax Income (+$)
Income Before Tax-101,089
Tax Provision-59
Net Income From Continuing Ops-111,141-101,148
Net Income-101,167
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses107,522
Total Other Income/Expenses Net6,4331,700
 

Technical Analysis of X4 Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of X4 Pharmaceuticals Inc. The general trend of X4 Pharmaceuticals Inc is BULLISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine X4 Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (42.9%) Bearish trend (-42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of X4 Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.6 < 1.6 < 1.68.

The bearish price targets are: 1.11 > 1.11 > 1.07.

Tweet this
X4 Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of X4 Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 10/14.
The longshort score for the Moving Averages is 6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

X4 Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of X4 Pharmaceuticals Inc. The current macd is 0.0374382.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the X4 Pharmaceuticals Inc price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for X4 Pharmaceuticals Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the X4 Pharmaceuticals Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
X4 Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartX4 Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of X4 Pharmaceuticals Inc. The current adx is 31.11.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy X4 Pharmaceuticals Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
X4 Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of X4 Pharmaceuticals Inc. The current sar is 1.40012179.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
X4 Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of X4 Pharmaceuticals Inc. The current rsi is 52.24. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
X4 Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartX4 Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of X4 Pharmaceuticals Inc. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the X4 Pharmaceuticals Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
X4 Pharmaceuticals Inc Daily Stochastic Oscillator ChartX4 Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of X4 Pharmaceuticals Inc. The current cci is -71.31484335.

X4 Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartX4 Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of X4 Pharmaceuticals Inc. The current cmo is -0.59421873.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
X4 Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartX4 Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of X4 Pharmaceuticals Inc. The current willr is -64.1509434.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that X4 Pharmaceuticals Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
X4 Pharmaceuticals Inc Daily Williams %R ChartX4 Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of X4 Pharmaceuticals Inc.

X4 Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of X4 Pharmaceuticals Inc. The current atr is 0.12613494.

X4 Pharmaceuticals Inc Daily Average True Range (ATR) ChartX4 Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of X4 Pharmaceuticals Inc. The current obv is 16,593,423.

X4 Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartX4 Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of X4 Pharmaceuticals Inc. The current mfi is 43.72.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
X4 Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartX4 Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for X4 Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-01STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-24CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-22ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-02RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

X4 Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of X4 Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.240
Ma 20Greater thanMa 501.343
Ma 50Greater thanMa 1001.103
Ma 100Greater thanMa 2000.947
OpenGreater thanClose1.180
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of X4 Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on X4 Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about X4 Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about X4 Pharmaceuticals Inc

I send you an email if I find something interesting about X4 Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about X4 Pharmaceuticals Inc.

Receive notifications about X4 Pharmaceuticals Inc in your mailbox!